Neurological disorder

THE BETA GROUP: Do Race Horses Have to be Killed for a Fractured Leg?

Retrieved on:

금요일, 5월 3, 2024

Leg, Horse, Component, System, Hope, Neurological disorder, Rib, History, Anatomy, Silicon, Spinal cord, Athlete, Memory, Tell

One year ago, 12 horses died just before and after, sparking outrage in the press: https://www.nytimes.com/search?query=Kentucky+derby+horse+deaths

Key Points:

One year ago, 12 horses died just before and after, sparking outrage in the press: https://www.nytimes.com/search?query=Kentucky+derby+horse+deaths
Why is it that human athletes can be healed for a fractured leg, but equine athletes are often times "euthanized"?
Obviously, no veterinarian wants to kill a horse for a fractured leg!
But these outcomes are fueling the fire for Animal Rights groups to end horse racing.
Horses, however, have a unique anatomy and that makes it very challenging if not impossible to rehabilitate horses with fractured legs.

Elara Caring Partners with Constant Therapy to Deliver First AI-Driven Speech-Language and Cognitive Therapy at Scale

Retrieved on:

수요일, 4월 17, 2024

Brain, Stroke, Neurological disorder, Health, Population health, Partnership, Dementia, Patient, Caregiver, DSM-IV codes, Constant, Pharmaceutical industry

Insights available through Constant Therapy’s enterprise platform complement Elara Caring’s use of population health data, improving care plans for patients with neurological disorders.

Key Points:

Insights available through Constant Therapy’s enterprise platform complement Elara Caring’s use of population health data, improving care plans for patients with neurological disorders.
With the partnership, Elara clinicians can now deliver a highly-personalized course of therapeutic exercises – and measure patient progress – to best meet the needs of patients recovering from conditions such as stroke, brain injury or dementia.
Simultaneously, Elara patients are given unlimited access to the Constant Therapy mobile app – allowing them to maintain engagement with their therapy program outside of their scheduled clinical visits.
“Elara Caring is well recognized for its use of advanced technology and data insights that help proactively treat and monitor patients,” said Mark Salley, VP of Innovations and Rehab Solutions, Elara Caring.

GLUCOTRACK ANNOUNCES EXPANSION OF ITS CONTINUOUS GLUCOSE MONITORING TECHNOLOGY TO EPIDURAL GLUCOSE MONITORING

Retrieved on:

화요일, 4월 16, 2024

Pain, Electrode, SCS, Epidural space, Neurological disorder, Animal, Diabetes, CGM, Electricity, Doctor of Philosophy, Blood, PDN, Patient, Spinal cord stimulator, Spinal cord, Glucose, Hypoesthesia, Quality of life, Medical device

Rutherford, NJ, April 16, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced that it is expanding its glucose monitoring technology to include measuring glucose in the epidural space. A continuous glucose monitoring system that takes readings in the spinal epidural space may be integrated with existing treatments for patients with Painful Diabetic Neuropathy (PDN).

Key Points:

A continuous glucose monitoring system that takes readings in the spinal epidural space may be integrated with existing treatments for patients with Painful Diabetic Neuropathy (PDN).
Combining SCS and continuous glucose monitoring (CGM) could provide several possible advantages, such as simplifying device management for those patients.
This is the second application of Glucotrack’s technology for implantable continuous glucose monitoring, in addition to its development of a long-term Continuous Blood Glucose Monitoring (CBGM) system.
The results demonstrated the Glucotrack epidural glucose values closely tracked both the blood glucose and subcutaneous CGM values.

Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting

Retrieved on:

월요일, 4월 22, 2024

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be presented at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting.

Key Points:

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be presented at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting.
The data show that the NGN-401 gene therapy candidate has been generally well-tolerated, and there have been no treatment-emergent or procedure-related serious adverse events or signs of MeCP2 overexpression-related toxicity observed in any patient, including a patient with a mild variant predicted to result in residual MeCP2 function.
“Rett syndrome is a complex neurological disorder with a narrow therapeutic window, and conventional gene therapy approaches have been unable to provide therapeutic protein levels without detrimental overexpression.
Therefore, we believe it is important to share this safety update at the ASGCT Meeting, in advance of our expected fourth quarter 2024 interim efficacy read-out, as we have multiple months of data from three patients showing NGN-401 has been generally well-tolerated.”
Title: Preliminary Safety Results from the Ph1/2 study of NGN-401, a Novel Regulated Gene Therapy for Rett Syndrome

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Retrieved on:

화요일, 4월 23, 2024

CAMPBELL, Calif., April 23, 2024 /PRNewswire/ -- Vivalink, a leading provider of digital healthcare solutions, announces its collaboration with the Rett Syndrome Research Trust (RSRT) to advance research into Rett syndrome, a rare neurological disorder. As part of this partnership, Vivalink is providing its Multi-Vital ECG wearable technology and data services for heart rate and oxygen saturation monitoring to support RSRT's new VIBRANT study, aimed at assessing autonomic dysfunction in individuals with Rett syndrome.

Key Points:

CAMPBELL, Calif., April 23, 2024 /PRNewswire/ -- Vivalink , a leading provider of digital healthcare solutions, announces its collaboration with the Rett Syndrome Research Trust (RSRT) to advance research into Rett syndrome, a rare neurological disorder.
Vivalink's advanced wearable devices provide an important opportunity to expedite drug development in the pursuit of a cure for Rett Syndrome.
"We are excited to partner with the Rett Syndrome Research Trust in their pioneering study," said Aaron Timm, Chief Commercial Officer at Vivalink.
"We hope to empower researchers with the tools they need to make meaningful advancements in understanding and treating Rett syndrome."

Intranasal Delivery of shRNA Edits to Silence 5-HT2A Receptor Shows Promise in Enhancing Memory and Alleviating Anxiety

Retrieved on:

목요일, 3월 21, 2024

In a groundbreaking study, they successfully used a non-invasive intranasal delivery platform to administer short-hairpin RNA (shRNA) that targets the 5-HT2A receptor resulting in long-lasting improvements in memory and reduced anxiety in animal models.

Key Points:

In a groundbreaking study, they successfully used a non-invasive intranasal delivery platform to administer short-hairpin RNA (shRNA) that targets the 5-HT2A receptor resulting in long-lasting improvements in memory and reduced anxiety in animal models.
Neurological disorders such as Mild Cognitive Impairment (MCI), depression, and anxiety disorders pose significant challenges to public health worldwide.
In this study, the researchers designed shRNA sequences to specifically target and silence the human HTR2A gene, which is associated with anxiety and memory.
The ability to bypass the blood-brain barrier using intranasal delivery opens up new avenues for precision-based therapeutics in neurological disorders."

FDA Approves Nonsteroidal Treatment for Duchenne Muscular Dystrophy

Retrieved on:

목요일, 3월 21, 2024

SILVER SPRING, Md., March 21, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Duvyzat (givinostat) oral medication for the treatment of Duchenne Muscular Dystrophy (DMD) in patients six years of age and older.

Key Points:

SILVER SPRING, Md., March 21, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Duvyzat (givinostat) oral medication for the treatment of Duchenne Muscular Dystrophy (DMD) in patients six years of age and older.
Duvyzat is the first nonsteroidal drug approved to treat patients with all genetic variants of DMD.
"This approval provides another treatment option to help reduce the burden of this progressive, devastating disease for individuals impacted by DMD regardless of genetic mutation."
DMD is the most common childhood form of muscular dystrophy and typically affects males.

Digital Health in the Neurology Market worth $167.58 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.

Retrieved on:

화요일, 3월 19, 2024

There are strict regulatory frameworks in place in several locations that affect the digital health sector of neurology.

Key Points:

There are strict regulatory frameworks in place in several locations that affect the digital health sector of neurology.
While these rules are essential for protecting patients' health, they can hinder the development and rollout of innovative digital health solutions in neurology.
These limitations are expected to limit the expansion of the digital health market in neurology during the next few years.
The North American digital health in neurology market is expected to register a large market share in the revenue.

Digital Health in the Neurology Market worth $167.58 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.

Retrieved on:

화요일, 3월 19, 2024

There are strict regulatory frameworks in place in several locations that affect the digital health sector of neurology.

Key Points:

There are strict regulatory frameworks in place in several locations that affect the digital health sector of neurology.
While these rules are essential for protecting patients' health, they can hinder the development and rollout of innovative digital health solutions in neurology.
These limitations are expected to limit the expansion of the digital health market in neurology during the next few years.
The North American digital health in neurology market is expected to register a large market share in the revenue.

ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option

Retrieved on:

목요일, 2월 22, 2024

ASC, Traumatic brain injury, Inflammation, Quality of life, Neurological disorder, Multiple sclerosis, University, Intellectual disability, Therapy, Neurology, Super Meat Boy, Patient, DSM-IV codes, Clinical trial, Inflammasome, IND, DRS, Research, Pharmaceutical industry

A growing body of evidence supports that activation of more than one type of inflammasome contributes to development of common neurological diseases, and that extracellular ASC specks are involved in disease progression.

Key Points:

A growing body of evidence supports that activation of more than one type of inflammasome contributes to development of common neurological diseases, and that extracellular ASC specks are involved in disease progression.
The white paper summarizes the preclinical research of leading inflammasome experts, Drs.
The white paper then summarizes data from preclinical research led by Drs.
Keane, de Rivero Vaccari, and their colleagues currently have research underway in Parkinson’s disease that was funded through a grant with the Michael J.